Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | BCL9 | O00512 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.47 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.47 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20729821 | 0.88 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL27404548 | 0.86 | HTR2A (0.46) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL22430913 | 0.86 | HTR2A (0.63) | HTR2ABCL9CTNNB1GAAALDH1A1 | |
| SCHEMBL25565896 | 0.85 | HTR2A (0.46) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL409598 | 0.83 | HTR2A (0.59) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL30880314 | 0.82 | HTR2A (0.56) | HTR2AGAASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL5526504 | 0.82 | HTR2A (0.58) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL11301568 | 0.82 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL27410089 | 0.82 | HTR2A (0.52) | HTR2ABCL9CTNNB1GAAPTPN7 | |
| SCHEMBL22430886 | 0.82 | HTR2A (0.47) | HTR2ABCL9CTNNB1GAAPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606863-B2 | Bioluminescent detection of DNA synthesis | PROMEGA CORPORATION (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240208898-A1 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208898-A1 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4337646-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | Promega Corporation (US) | 2024-03-20 | — | — | EP | disclosed |
| EP-4313013-A2 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | Dana-Farber Cancer Institute, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279629-A | Enamine N-oxide: synthesis and use in hypoxia responsive prodrugs and imaging agents | 达纳－法伯癌症研究所公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20220396830-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | PROMEGA CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-20220396830-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | PROMEGA CORPORATION | 2022-12-15 | — | — | US | disclosed |
| WO-2022241249-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | PROMEGA CORPORATION (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2022204344-A2 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-10604547-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2020-03-31 | — | — | US | disclosed |
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
| EP-3452492-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | Novartis AG (CH) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191579-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS AG (CH) | 2017-11-09 | — | — | WO | disclosed |
| CN-103834002-B | Based on sensitivity to acid Zorubicin prodrug and preparation method thereof and the application of polyoxyethylene glycol | SUZHOU UNIVERSITY (CN) | 2016-02-17 | — | — | CN | disclosed |
| CN-103834002-B | Based on sensitivity to acid Zorubicin prodrug and preparation method thereof and the application of polyoxyethylene glycol | SUZHOU UNIVERSITY (CN) | 2016-02-17 | — | — | CN | disclosed |
| CN-103834002-A | Preparation method and application of acid sensitive doxorubicin prodrug based on polyethylene glycol | UNIV SOOCHOW | 2014-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | RNGTT, RNASE1, RNMT | HTR2A 4518/4885BCL9 1207/4885CTNNB1 4536/4885 |
| US-12606863-B2 | Bioluminescent detection of DNA synthesis | PCNA, MKI67, POLL | HTR2A 2014/4885BCL9 419/4885CTNNB1 295/4885 |
| US-10604547-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | RNGTT, RNASE1, RNMT | HTR2A 4518/4885BCL9 1207/4885CTNNB1 4536/4885 |
| US-20220396830-A1 | BIOLUMINESCENT DETECTION OF DNA SYNTHESIS | RNGTT, NUDT1, DNTT | HTR2A 2293/4885BCL9 2222/4885CTNNB1 2521/4885 |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | HTR2A 4518/4885BCL9 1207/4885CTNNB1 4536/4885 |
| US-20240208898-A1 | ENAMINE N-OXIDES: SYNTHESIS AND APPLICATION TO HYPOXIA-RESPONSIVE PRODRUGS AND IMAGING AGENTS | ENO1, HIF1A, HIF1AN | HTR2A 485/4885BCL9 3614/4885CTNNB1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.